What We're Reading: Obesity Rises Among US Women
What we're reading, June 8, 2016: obesity rate among women reaches record high; abuse-resistant opioid recommended for approval by advisory panel; and Gilead does not owe Merck money in drug-patent dispute.
The rate of obesity among women in the United States has reached a record high.
Teva’s abuse-resistant opioid has received a recommendation for approval by an FDA advisory panel. The long-acting painkiller is designed for patients with pain severe enough that it requires around-the-clock treatment,
Gilead Sciences Inc. will not have to pay Merck & Co. over a drug-patent dispute. A judge has reversed a jury decision after determining Merck’s attorney involved with obtaining patents for hepatitis C drugs engaged in misconduct,
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025